Welcome to our dedicated page for Innate Pharma S.A. ADS news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. ADS stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma announced on December 11, 2020, that it will cease commercialization of Lumoxiti in the US and EU, returning these rights to AstraZeneca. The decision stems from lower-than-expected sales and the impact of the COVID-19 pandemic, prompting Innate to refocus its investments on R&D. A transition plan is set to ensure Lumoxiti's availability during the handover, with commercialization responsibilities returning to AstraZeneca in 2021. As of June 30, 2020, Lumoxiti's intangible assets were valued at €45.2 million.
Innate Pharma (Euronext: IPH, Nasdaq: IPHA) announced upcoming data presentation for its lead candidate, monalizumab, at the ESMO Immuno-oncology Virtual Congress from Dec. 9-12, 2020. The presentation will focus on a Phase 2 study of monalizumab in combination with cetuximab for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN) previously treated with platinum-based chemotherapy. AstraZeneca recently initiated a Phase 3 trial, INTERLINK-1, for the same combination. The agreement with AstraZeneca includes potential payments of up to $1.275 billion.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced its 2021 financial calendar. Key dates include:
- March 18, 2021: 2020 financial statements
- May 11, 2021: Q1 2021 revenue
- May 28, 2021: Annual General Shareholders Meeting
- September 15, 2021: Half-year financial statements
- November 16, 2021: Q3 2021 revenue
Reports will be released before market open CET. Innate Pharma focuses on oncology, aiming to enhance patient outcomes through innovative immune-based therapies.
Innate Pharma announced significant milestones in its latest report, including lacutamab's PRIME designation for Sézary Syndrome by the EMA, complementing its earlier FDA Fast Track designation. The initiation of the Phase 3 monalizumab study by AstraZeneca triggered a $50 million milestone payment, enhancing the company’s cash position to €163.6 million as of September 30, 2020. These achievements underscore Innate's strategic focus on developing proprietary therapies and improving patient outcomes.
Innate Pharma announced that the European Medicines Agency (EMA) has granted PRIME designation to lacutamab, its first-in-class anti-KIR3DL2 antibody, for treating patients with relapsed or refractory Sézary syndrome. This designation is based on positive efficacy and safety data from ongoing clinical trials, including the Phase 1 and Phase 2 TELLOMAK study. Lacutamab is designed to target unmet medical needs in cutaneous T-cell lymphoma patients, showing promise for those who have undergone multiple previous therapies.
Innate Pharma announced participation in several virtual investor conferences. Key events include the Bryan Garnier Conference on November 17, the Jefferies Conference on November 18, and the SVB Leerink Oncology Day on November 19, 2020. The Evercore ISI HealthCONx is scheduled for December 1-3, 2020, with a fireside chat on December 2. Presentations will be available for replay on the company's website. Innate Pharma focuses on innovative oncology treatments, notably Lumoxiti, approved for hairy cell leukemia, and has partnerships with major biopharmaceutical firms.
Innate Pharma announced the launch of HopeConnectLearn, a new online resource for the hairy cell leukemia community. This platform aims to provide education and connection for patients and caregivers, covering the disease from diagnosis to relapse. Hairy cell leukemia accounts for 2-3% of adult leukemia cases in the U.S., with around 1,000 new diagnoses annually. The initiative seeks to empower patients with information, fostering community support.
Innate Pharma SA (Nasdaq: IPHA) announced that AstraZeneca has dosed the first patient in the Phase 3 clinical trial, INTERLINK-1, evaluating monalizumab with cetuximab for R/M SCCHN patients previously treated with platinum-based therapies. This milestone triggers a $50 million payment from AstraZeneca, enhancing Innate's cash position through 2022. The trial aims to investigate overall survival among approximately 600 patients. Prior studies indicated a response rate of 20-27.5% for the combination, highlighting an unmet medical need in this patient demographic.
On October 1, 2020, Innate Pharma announced its total number of shares outstanding and voting rights, complying with French regulations. The company has 78,981,290 ordinary shares and additional 6,921 and 7,581 preferred shares from 2016 and 2017, respectively. Total theoretical voting rights stand at 79,799,621, with 79,781,046 exercisable voting rights. Innate Pharma, focused on oncology and immunotherapy, aims to enhance cancer treatment through its innovative antibody pipeline, including Lumoxiti, approved by the FDA.
Innate Pharma reported significant progress in its clinical pipeline, resuming enrollment in the Phase 2 lacutamab study for Sézary syndrome and mycosis fungoides. The Phase 3 study for monalizumab, partnered with AstraZeneca, is set to trigger a $50 million milestone payment upon initiation. The company holds a cash position of €184.6 million as of June 30, 2020, despite a decrease in revenue to €36.7 million from €59.2 million in the prior year. Operating expenses slightly increased to €46 million, and a net loss of €10.3 million was reported, compared to a net income of €13.2 million in H1 2019.
FAQ
What is the current stock price of Innate Pharma S.A. ADS (IPHA)?
What is the market cap of Innate Pharma S.A. ADS (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
